Aug 2026· ACS Central Science· Vol 12, pp. 1223 - 1236· 0 citations· 48 references
Medicine
TL;DR
A chemically masked IL-2 prodrug (Cm-proIL2) that enables tumor-microenvironment-responsive cytokine activation through tumor-associated protease cleavage to demonstrate the feasibility of chemically masked, tumor-responsive cytokine activation as a strategy for improving the therapeutic index of IL-2-based immunotherapies.
Abstract
Interleukin-2 (IL-2) is a potent mediator of T-cell activation with significant potential for cancer immunotherapy, yet its clinical utility is severely constrained by its narrow therapeutic window. Here we report a chemically masked IL-2 prodrug (Cm-proIL2) that enables tumor-microenvironment-responsive cytokine activation through tumor-associated protease cleavage. Site-specific conjugation of a poly(ethylene glycol) (PEG) moiety selectively masks peripheral receptor engagement, while PEG removal within the tumor microenvironment restores IL-2 receptor binding and reduces molecular size, thereby enhancing intratumoral lymphocyte penetration and effector T cell functionality. Building on this modular platform, we further engineered a PD-1-targeted nanobody fusion, PD1-Cm-proIL2, to enable the cis delivery of IL-2 activity to PD-1+ tumor-infiltrating T cells. PD1-Cm-proIL2 induces robust antitumor immunity, resulting in complete tumor regression and durable protection upon tumor rechallenge in a murine colorectal cancer model. Together, these findings demonstrate the feasibility of chemically masked, tumor-responsive cytokine activation as a strategy for improving the therapeutic index of IL-2-based immunotherapies.
Interleukin-12 (IL-12) potently promotes the recruitment and activation of immune cells within the tumor microenvironment (TME), highlighting its immense potential for cancer therapy. However, its dose-limiting systemic toxicity and short half-life severely hinder its clinical translation. Here, we design a tumor-condi...
Xi Wang, Liu Yang, Yu-Hao Hou et al.· International Journal of Mol...· 0 citations
Abstract Background Targeting the high-affinity interleukin-2 receptor (IL-2R) on CD8+ T effector cells elicits potent antitumor responses that are augmented when co-administered with programmed cell death protein 1 (PD-1) blockade. Methods Using the mouse IL-2/CD25 fusion protein (mIL-2/CD25) at a high dose (HD) and a...
Kathryn M. Laporte, Janika Põder, D. Ivanova et al.· Journal for ImmunoTherapy of...· 0 citations
Preclinical results validate a rational design approach to overcome the limitations of IL-2 therapy and support the clinical evaluation of Alb–IL-2var RNA-LNP for solid cancers.
Mathias Vormehr, L. Kranz, A. Muik et al.· Science Advances· 0 citations
Tumor-targeting cytokines have emerged as a promising strategy for cancer immunotherapy, although their mechanisms of action often remain complex. In this study, we develop an approach by combining tumor-targeted IL-10 (CmAb-(IL10)2) with IL-2 (CmAb-IL2) to enhance antitumor immunity while minimizing immune-related adv...
Zhi-Chen Sun, Yi-Fei Hu, Casey Moore et al.· Nature Communications· 0 citations
Pancreatic ductal adenocarcinoma (PDAC) features dense desmoplastic stroma that impedes drug penetration and immune infiltration, and promotes therapeutic resistance. As a central driver of stromal fibrosis and immunosuppression, TGF-β represents an attractive target for overcoming these barriers. Herein, we report nov...
Zhe Li, Xiao-Meng Liu, Xiao-Ya Wang et al.· Journal of Medicinal Chemist...· 0 citations
Cancer immunotherapies have achieved meaningful clinical benefit but remain limited by systemic toxicities that restrict the use of potent immune modulators. CD47-targeting antibodies promote tumor cell phagocytosis but are hindered by hematologic toxicity, while IL-2 activates cytotoxic lymphocytes but induces broad,...
Elise Léchine, Laura Cons, L. Garnier et al.· Cancer immunology research· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.